Dare Bioscience awarded grant for prevention of idiopathic preterm birth

Dare Bioscience was awarded a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health in the amount of approximately $385,000 to support activities related to the conduct and completion of proof-of-concept target validation studies in support of a potential new approach for the prevention and treatment of idiopathic preterm birth. Dare will collaborate with its sub awardee, the Lockwood Laboratory at the University of South Florida Morsani College of Medicine, on the grant-funded activities. Under an exclusive option agreement with the University of South Florida Research Foundation, a nonprofit Florida corporation that is a direct support organization of USF, Dare has an exclusive right, and not an obligation, to elect to negotiate to acquire the exclusive worldwide rights to patents and know-how controlled by USFRF related to this research in the field of human reproduction during an option period which extends through this NIH-funded development project.